One-Time gene injection could end frequent eye shots for wet AMD
NCT ID NCT05903794
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration (nAMD), a condition where abnormal blood vessels damage central vision. The therapy was injected into the eye to block these vessels. The main goal was to check safety and tolerability, not yet to prove it works. If safe, larger studies could explore whether it reduces the need for repeated anti-VEGF injections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EXG102-031 (a gene therapy injected into the eye to block abnormal blood vessel growth)
- What this could lead to
- If successful, this could lead to a one-time gene therapy that reduces the need for frequent eye injections in people with wet age-related macular degeneration.
- What could go wrong
- This is a very early Phase 1 trial with only 12 people, focused on safety. It is too small to prove effectiveness, and gene therapy carries risks like inflammation or vision changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Erie Retina Research
Erie, Pennsylvania, 16507, United States
-
Sierra Eye Associates
Reno, Nevada, 89502, United States